Lipids and lipid compositions for the delivery of active agents

Patent metadata

Field	Value
Publication number	US-10906867-B2
Application number	US-201816013048-A
Country	US
Kind code	B2
Filing date	Jun 20, 2018
Priority date	Dec 19, 2013
Publication date	Feb 2, 2021
Grant date	Feb 2, 2021

Abstract

This invention provides for a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein R 1 -R 4 , L 1 , n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

First claim

What is claimed is:

1. A lipid composition comprising a compound of formula (II) or a pharmaceutically acceptable salt thereof,

wherein:
R 1 is selected from the group consisting of:

R 2 and R 3 are each, independently, selected from the group consisting of C 7-22 alkyl, C 12-22 alkenyl, and C 3-8 cycloalkyl, each optionally substituted with 1, 2, or 3 moieties selected from the group consisting of C 1-8 alkyl groups,

R 4 is selected from the group consisting of hydrogen, C 1-14 alkyl,

2. The lipid composition according to claim 1 , further comprising a biologically active agent.

3. A pharmaceutical composition comprising the lipid composition according to claim 2 , and a pharmaceutically acceptable carrier or excipient.

4. The composition of claim 2 , wherein the composition comprises a RNA molecule that encodes an immunogen, optionally wherein the RNA is a self-replicating RNA.

5. The composition of claim 4 , wherein the immunogen can elicit an immune response in vivo against a bacterium, a virus, a fungus or a parasite.

6. The lipid composition according to claim 1 , wherein the lipid composition is in the form of a lipid nanoparticle.

7. A pharmaceutical composition comprising liposomes and immunogen-encoding self-replicating RNA molecules, wherein the liposomes comprise the lipid composition of claim 1 , and wherein at least half of the molar percentage of the RNA molecules are encapsulated in the liposomes.

8. The composition of claim 7 , wherein the immunogen can elicit an immune response in vivo against a bacterium, a virus, a fungus or a parasite.

9. The lipid composition according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof comprises R 2 selected from the group consisting of:

10. The lipid composition according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof comprises R 3 selected from the group consisting of:

11. The lipid composition according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof comprises at least one of R 2 and R 3 is

12. The lipid composition according to claim 1 , further comprising a neutral lipid.

13. The lipid composition according to claim 1 , further comprising a helper lipid.

14. The lipid composition according to claim 1 , further comprising a stealth lipid.

15. The lipid composition according to claim 1 , further comprising a neutral lipid, a helper lipid, and a stealth lipid.

16. The lipid composition according to claim 15 , wherein the lipid composition is in the form of a lipid nanoparticle.

17. A lipid composition comprising a compound, wherein the compound is:

(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof.

18. A lipid composition comprising a compound, wherein the compound is:

(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(dimethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof.

19. A lipid composition comprising a compound, wherein the compound is:

(9Z,12Z)-3-((4,4-bis(octyl oxy)butanoyl)oxy)-2-(((((1-ethylpiperidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof.

20. A lipid composition comprising a compound, wherein the compound is:

(9Z,9′Z,12Z,12′Z)-2-(((1,3-dimethylpyrrolidine-3-carbonyl)oxy)methyl)propane-1,3-diyl bis(octadeca-9,12-dienoate), or a pharmaceutically acceptable salt thereof.

Assignees

• Novartis Ag

Inventors

• Brito Luis
• Chen Delai
• Gamber Gabriel Grant
• Geall Andrew
• Love Kevin
• Zabawa Thomas
• Zecri Frederic

Classifications

• C07D205/04

  having no double bonds between ring members or between ring members and non-ring members · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/12

  Viral antigens · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title